Article info
PDFHepatology
Original research
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
- Correspondence to Professor Philip Meuleman, Laboratory of Liver Infectious Diseases (LLID), Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, Ghent University, Gent, Belgium; philip.meuleman{at}ugent.be; Professor Matti Sällberg, Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden; matti.sallberg{at}ki.se
Citation
Novel prime-boost immune-based therapy inhibiting both hepatitis B and D virus infections
Publication history
- Received February 18, 2022
- Accepted July 29, 2022
- First published August 17, 2022.
Online issue publication
May 31, 2023
Article Versions
- Previous version (31 May 2023).
- Previous version (31 May 2023).
- You are viewing the most recent version of this article.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.